|  |  |  |
| --- | --- | --- |
| **DRUG TYPE OR USE** | **PURPOSE** | **PBAC OUTCOME** |
| **Delisting over the counter drugs (OTC)** | To provide further advice in relation to drugs that are listed on the PBS which are also available for OTC purchase and which may be appropriate to remove from the PBS.  The PBAC previously provided advice on this matter at the April 2015 special meeting. | The PBAC considered submissions from sponsors and other stakeholders and updated its advice to the Minister to reflect those submissions.  The PBAC noted the issues raised by stakeholders regarding maintenance of access for Aboriginal or Torres Strait Islander peoples, and for paraplegic and quadriplegic patients who rely on current access arrangements.    The PBAC recommended that it would be appropriate for the PBS listings to be amended to restrict access to patients who are Aboriginal or Torres Strait Islander. The PBAC noted that such amendments would maintain access via the Closing the Gap PBS Co-payment Measure and via Section 100 Aboriginal Health Services.  The PBAC recommended that the PBS listings for bisacodyl suppositories and glycerol suppositories be amended to provide access specifically for paraplegic and quadriplegic patients for supply under the Section 100 Paraquad programme. |